Trial · NCT02848443
Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer
NCT02848443, Phase 1, Completed, Institut de Recherches Internationales Servier
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer. Trials, record NCT02848443. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02848443
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer
- NCT number
- NCT02848443
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 78 participants, actual
- Lead sponsor
- Institut de Recherches Internationales Servier
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Trifluridine/tipiracil hydrochloride (S 95005), Oxaliplatin, Bevacizumab, Nivolumab
- First posted
- 2016-07-28
- Last updated
- 2024-07-25
- Other registries' IDs
- eudract:2015-004894-34
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Tolerated Dose (MTD) of S95005 when given in combination with oxaliplatin | up to 4 weeks after the first treatment administration | |
| Primary | Dose Limiting Toxicity (DLT) of S95005 when given in combination with oxaliplatin | up to 4 weeks after the first treatment administration | |
| Primary | Number of participants with adverse events as a measure of safety and tolerability for S95005-oxaliplatin. | through study completion, an average of 9 months | Adverse event reporting will be graded following the National Cancer Institute of Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 |
| Primary | Changes in standard hematology as a measure of safety and tolerability for S95005-oxaliplatin | through study completion, an average of 9 months | |
| Primary | Changes in biochemistry as a measure of safety and tolerability for S95005-oxaliplatin | through study completion, an average of 9 months | |
| Primary | Changes in coagulation as a measure of safety and tolerability for S95005-oxaliplatin | through study completion, an average of 9 months | |
| Primary | Changes in urinalysis as a measure of safety and tolerability for S95005-oxaliplatin | through study completion, an average of 9 months | |
| Primary | Changes in vital signs as a measure of safety for S95005-oxaliplatin | through study completion, an average of 9 months | Vital sign measurements will include temperature, systolic and diastolic blood pressure, heart rate, and respiratory rate. |
| Primary | Changes in ECOG (Eastern Cooperative Oncology Group) performance status as a measure of safety and tolerability for S95005-oxaliplatin | through study completion, an average of 9 months | |
| Secondary | Antitumor activity assessed by RECIST (Response Evaluation Criteria in Solid Tumors) and CEA (Carcinoembryonic Antigen) | through study completion, an average of 9 months |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02848443
GET https://conductscience.org/api/trials/v1/NCT02848443/registered?page=2